🧾 What This Document Is

This is a Form 8-K filing, which companies use to announce major events to investors. Attached is a press release announcing that Aprea Therapeutics has closed a $30 million private funding round. This isn't a regular stock sale to the public; it was a direct deal with a specific group of investors.

🏢 What The Company Does

👉 In simple terms, Aprea is a biotech company trying to create smarter cancer drugs. They focus on "precision medicine," which means they design treatments that target specific genetic markers in a patient's tumor. Their main goal is to kill cancer cells while sparing healthy ones. Their leading drug candidate, APR-1051, is designed to block a protein called WEE1, which cancer cells rely on to repair themselves and survive.

💰 Financial Highlights

The company raised approximately $30 million in gross proceeds before fees. This is a significant cash injection for a small clinical-stage company.

The Deal Mechanics: Instead of just selling stock, they sold a combination of "pre-funded warrants" and regular warrants to purchase up to about 37.2 million shares each.
Key Price Points: The pre-funded warrants were priced near $0.807 per share, and the regular warrants have an exercise price of $0.683 per share. They expire at the end of 2029.

👉 Why it matters: This structure allows investors to buy into the company at a fixed price, providing immediate capital and potentially future investment if they exercise the warrants. The relatively low share prices reflect the company's current stock valuation.

🚀 Key Moves: What The Money Is For

The net proceeds will fund two main areas:

General corporate operations.
Research & development expenses, specifically for their lead drug, APR-1051.

The CEO, Oren Gilad, stated the funding is "transformational" and will accelerate their ongoing clinical trial (the ACESOT-1051 study). Their immediate plan is to expand the trial to focus on specific cancers where they believe their drug will work best: uterine serous carcinoma (USC) and a type of platinum-resistant ovarian cancer (PROC) that overexpresses cyclin E. They aim to enroll at least 50 patients in these groups.

🤝 The Investors & The Deal

This was an "oversubscribed" round, meaning there was more demand from investors than shares available. It was led by Soleus Capital, with other new investors like Vestal Point Capital and Squadron Capital Management. Notably, existing investors and company insiders also participated.

Placement Agents: The deal was facilitated by Oppenheimer & Co. Inc. (lead) and Maxim Group LLC (co-lead).

👉 Why it matters: Having major biotech-focused funds and company insiders invest their own money is a strong vote of confidence in the science and the plan.

🔮 What's Next

The company has a clear, immediate roadmap:

Use the cash to push forward the clinical trial for APR-1051.
Sharpen their focus on the specific patient populations (USC and cyclin E-overexpressing PROC) where they see the best chance of success.
File a registration statement with the SEC to allow these private investors to eventually resell their shares to the public.

⚖️ Big Picture: Strengths & Risks

👍 Strengths: The company successfully raised crucial funding in a tough market, validated by sophisticated biotech investors. This gives them the runway to generate more clinical data for their lead drug. Their targeted approach to cancer therapy is aligned with modern oncology trends.
⚠️ Risks: The company is still clinical-stage, meaning it has no approved products or revenue from sales. Its success is entirely dependent on whether APR-1051 can prove effective and safe in trials. The private placement shares and warrants, once registered for resale, could put downward pressure on the stock price.

🧠 The Analogy

Imagine Aprea is a team of mechanics building a custom engine for a specific type of race car. They were running low on fuel (cash) to finish the project. This private placement is like a group of expert racing sponsors coming in, filling up their tank, and saying, "Don't try to build for every track. Focus all your power on the two race conditions (cancer types) where this engine design will dominate."

📇 Key Contacts & People

Mike Moyer (LifeSci Advisors) - Contact for investor relations.
- Email: [email protected]
Oren Gilad, Ph.D. - President and Chief Executive Officer of Aprea Therapeutics.

🧩 Final Takeaway

Aprea Therapeutics secured a vital $30 million lifeline from specialized investors to fund the next phase of testing for its cancer drug, APR-1051. The money allows them to strategically focus their efforts on the cancer types most likely to respond, buying them time to prove the drug's value and advance toward a potential future partnership or approval.

Aprea Therapeutics, Inc. — 8-K Filing